Chairperson and Managing Director of Biocon, Kiran Mazumdar-Shaw announced in a tweet that she has tested positive for COVID-19. The billionaire entrepreneur took to the social media platform and said: "I have added to the Covid count by testing positive. Mild symptoms n I hope it stays that way."
The Biocon head had in July said that she was extremely encouraged by the clinical trials of Itolizumab--better known by its brand name ALZUMAb, which has received approval from the Indian drug regulator for treating COVID-19. The drug is being used by numerous doctors and over 150 people had recovered from coronavirus until July 13.
"This is a hospital-based treatment, it’s an infusion. It costs Rs 7,950 per vial – that’s the MRP cost and this is a treatment that has to be delivered in the hospital, it has to be carefully monitored,” she told CNBC-TV18 in an earlier interview.
I have added to the Covid count by testing positive. Mild symptoms n I hope it stays that way.
— Kiran Mazumdar Shaw (@kiranshaw) August 17, 2020
The Biocon head had in July said that she was extremely encouraged by the clinical trials of Itolizumab--better known by its brand name ALZUMAb, which has received approval from the Indian drug regulator for treating COVID-19. The drug is being used by numerous doctors and over 150 people had recovered from coronavirus until July 13.
"This is a hospital-based treatment, it’s an infusion. It costs Rs 7,950 per vial – that’s the MRP cost and this is a treatment that has to be delivered in the hospital, it has to be carefully monitored,” she told CNBC-TV18 in an earlier interview.
First Published: Aug 17, 2020 11:49 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!